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Huntington's disease (HD) is a fatal dominantly inherited neurodegenerative disorder caused by a CAG repeat expansion leading to an elongated polyglutamine stretch in huntingtin 1 . Mutant huntingtin (mHTT) is ubiquitously expressed in all cells but elicits selective cortical and striatal neurodegeneration in HD 2 . The mechanistic basis for such selective neuronal vulnerability remains unclear. A necessary step toward resolving this enigma is to define the cell types in which mHTT expression is causally linked to the disease pathogenesis. Using a conditional transgenic mouse model of HD, in which the mice express fulllength human mHTT from a bacterial artificial chromosome transgene (BACHD) 3 , we genetically reduced mHTT expression in neuronal populations in the striatum, cortex or both. We show that reduction of cortical mHTT expression in BACHD mice partially improves motor and psychiatric-like behavioral deficits but does not improve neurodegeneration, whereas reduction of mHTT expression in both neuronal populations consistently ameliorates all behavioral deficits and selective brain atrophy in this HD model. Furthermore, whereas reduction of mHTT expression in cortical or striatal neurons partially ameliorates corticostriatal synaptic deficits, further restoration of striatal synaptic function can be achieved by reduction of mHTT expression in both neuronal cell types. Our study demonstrates distinct but interacting roles of cortical and striatal mHTT in HD pathogenesis and suggests that optimal HD therapeutics may require targeting mHTT in both cortical and striatal neurons.
HD is characterized by progressive motor, psychiatric and cognitive deficits with an inexorable and fatal disease course 4 . HD postmortem brains show degeneration of the majority of striatal medium spiny neurons (MSNs) and, to a lesser extent, cortical pyramidal neurons (CPNs) 2 . Recent imaging studies suggest early and progressive loss of axons emanating from cortical neurons, including those projecting to the striatum, suggesting early dysfunction of corticostriatal connectivity in HD 5 . Currently, there is no therapy to prevent or slow the pathogenesis of HD.
Landmark genetic research has led to the identification of the causal genetic mutation for HD as a CAG repeat expansion translated into an expanded polyglutamine (polyQ) repeat in HTT protein 1 . HTT is ubiquitously expressed and capable of interacting with hundreds of brain proteins 6, 7 . Among the fundamental but unsolved questions in HD pathogenesis are what cell types mHTT primarily targets to elicit the disease, whether the vulnerable cortical and striatal neurons are affected through cell-autonomous or non-cell-autonomous mHTT toxicities 8 and whether disease processes in these brain regions are causally linked 9 . Answers to these questions are highly relevant to advancing therapeutics that directly target HTT [10] [11] [12] [13] .
To gain insight into such questions, we developed the BACHD model, which expresses human full-length mHTT (fl-mHTT) with a polyQ repeat of 97 glutamines (97Q) (ref. 3) . BACHD mice exhibit progressive motor and psychiatric-like behavioral deficits and selective cortical and striatal atrophy but lack overt striatal neuronal loss, hence partially recapitulating the HD phenotypes 3, 14 . BACHD is a conditional human genomic transgenic mouse model for HD featuring strategically placed loxP sites flanking mHTT exon 1 with the polyQ repeat, and hence the expression of fl-mHTT can be genetically reduced in Cre-expressing cell lineages ( Fig. 1a) .
To address whether mHTT expression in MSNs, CPNs or both could be responsible for aspects of disease phenotypes in BACHD, we first chose Cre-expressing mouse lines (Rgs9-Cre and Emx1-Cre) that have Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease specificity to these neuronal populations [15] [16] [17] [18] . Using distinct reporter mice with Cre-dependent expression of LacZ 19 or YFP (Ai3 mice) 20 , we confirmed that Rgs9-Cre selectively activates Cre-dependent gene expression in striatal MSNs ( Fig. 1b-d ) but not in other brain regions ( Supplementary Fig. 1a) . Consistent with prior studies, Emx1-Cre was active in the CPNs in the cortex and hippocampus, a subset of neurons in the amygdala and only a few neurons in the striatum (about 4%) and cerebellum ( Fig. 1c,d and Supplementary  Fig. 1a ). In the thalamus, Emx1-Cre; Ai3 mice showed YFP signal in the neuropil (probably in the axon terminals of the CPNs), but not in the neuronal cell bodies ( Supplementary Fig. 1a,b) . Thus, we confirmed that Emx1-Cre is a relatively cortex-specific Cre mouse line 15, 17, 18, 21 . Finally, we showed that Emx1-Cre; Rgs9-Cre doubletransgenic mice have efficient Cre-dependent gene expression in both CPNs and MSNs ( Fig. 1b-d ) but in very few other neuronal populations in the brain (Supplementary Fig. 1a ).
To generate a BACHD model series with genetic reduction of mHTT expression in MSNs, CPNs or both, we crossed BACHD mice with Emx1-Cre; Rgs9-Cre double-transgenic mice in the FVB/N inbred background. We generated a cohort of BACHD, BACHD; Emx1-Cre (BE), BACHD; Rgs9-Cre (BR) and BACHD; Emx1-Cre; Rgs9-Cre (BER) mice and used these mice to confirm selective reduction of mHTT mRNA and protein expression in distinct brain regions ( Fig. 1e,f) . Consistent with MSNs constituting a subset of the cells in the striatum (about 68%) 22 , we found that BR mice had selective partial reduction of mHTT protein expression (about 44%) in the striatum, but not in the cortex or cerebellum (Fig. 1e) . BER mice had significant reduction (about 80%) of mHTT expression compared to BACHD mice in both cortex and striatum, but not in the cerebellum ( Fig. 1e) . Notably, BE mice have about 70% reduction of mHTT protein expression in the cortex, but also about 40% reduction of mHTT protein expression in the striatum (Fig. 1e) . As in situ hybridization revealed that mHTT transcript levels are selectively reduced in BE cortex ( Fig. 1f ) and BER western blot analyses showed further significant reduction of mHTT protein expression in the striatum compared to either BE or BR littermates (i.e., mHTT protein expression is reduced in different striatal 'compartments' in BE and BR mice; Fig. 1e ), we conclude that the decrease of the striatal mHTT protein level in BE mice is caused by a decrease in the amount of mHTT protein that is synthesized in the cortical neurons and transported into the striatum within the corticostriatal and other corticofugal axons. Finally, western blot analyses also demonstrated that Cre-mediated reduction of mHTT expression in BACHD mice does not create any aberrant mHTT N-terminal fragments ( Supplementary Fig. 2) , and npg hence the phenotypic differences between BE, BR and BER mice can be interpreted in the context of genetic reduction of fl-mHTT expression in the specific cortical or striatal neuronal cell types. We next tested whether age-dependent motor and psychiatriclike behavioral deficits in BACHD mice can be improved via genetic reduction of mHTT expression in cortical or striatal neurons. We characterized a cohort of BACHD, BE, BR, BER and wild-type (WT) mice at 2, 6 and 12 months of age using rotarod (motor performance) and open-field (locomotion) tests, which are reliable assays of motor impairment in BACHD mice 3, 14 . BACHD mice showed the largest progression of rotarod deficit between 2 and 6 months of age, whereas the progression was smaller, but still statistically significant, between 6 and 12 months ( Fig. 2a-d and Supplementary Fig. 3 ) 3, 14 . Compared to WT mice, BR mice showed significant rotarod impairment at 6 and 12 months of age, as well as reduced locomotion at 12 months ( Fig. 2a-d and Supplementary Table 1 ). Although BE mice were still motorically impaired compared to WT mice, they did show significant, albeit partial, amelioration of rotarod performance at 6 months and open-field performance at 12 months compared to BACHD mice ( Fig. 2a,d and Supplementary Table 1 ). Of note, BER mice showed consistent and significant improvement of both motor phenotypes compared to BACHD mice at both testing ages ( Fig. 2a-d and Supplementary Table 1 ).
BACHD mice exhibited psychiatric-like behavioral deficits, including anxiety-like behavior in light-dark box exploration 14 and depression-like behavior in forced swimming test ( Fig. 2e,f) . These psychiatric-like behavioral deficits were significantly improved in both BE and BER mice compared to BACHD mice, whereas BR mice were still impaired compared to WT mice ( Fig. 2e,f) . The psychiatric-like behavioral deficits in BACHD and BR mice cannot be simply attributed to motor impairment that interferes with testing, as the initial latency to enter the dark compartment from the well-lit compartment (a measure of locomotor ability to perform the task) was not significantly different among the genotypes (Supplementary Fig. 4 ).
We next addressed where mHTT expression is critical for selective neurodegeneration and whether non-cell-autonomous disease mechanisms could contribute to the disease pathogenesis. Our prior study using a conditional mHTT exon 1 model showed that non-cell-autonomous mHTT fragment toxicities are likely to contribute to neuronal toxicities, but the precise cellular origins for such toxicities remain unclear 15 . The BACHD human genomic transgenic mouse model is particularly suitable for addressing this question because of its relatively accurate construct validity 23 and the manifestation of selective brain atrophy that partially mimics HD in these mice 3 . BACHD mice at 12 months showed selective forebrain weight loss and stereologically measured cortical and striatal volume loss ( Fig. 2g-i) . The cerebellar weights of all the BACHD genotypes did not significantly differ from each other or from those of the WT mice ( Supplementary  Fig. 5 ), supporting HD-like neurodegenerative pathology in this model 3 . In our cohort of HD model mice with brain-region-specific genetic reduction of fl-mHTT expression, only BER mice consistently showed significant amelioration of the forebrain weight loss ( Fig. 2g ) and cortical and striatal volume loss compared to BACHD mice ( Fig. 2h,i) . BR mice at 12months still showed significant brain atrophy in some (i.e., forebrain weight and striatal volume) but not all the readouts (Fig. 2g-i and Supplementary Table 1 ). Notably, BE mice did not show a significant difference in all three brain atrophy phenotypes compared with either BACHD or WT mice, suggesting that reduction of cortical mHTT expression alone can exert a behavioral benefit but may not be sufficient to ameliorate neurodegeneration phenotypes in BACHD ( Fig. 2g-i and Supplementary Table 1 ).
Our study used a comprehensive set of phenotypic readouts to define the neuronal targets in which mHTT synthesis substantially contributes to disease pathogenesis ( Table 1) npg BER mice consistently improved all disease phenotypes observed in BACHD mice. Second, genetic reduction of mHTT expression in the cortical neurons in BE mice caused amelioration of psychiatric-like behavioral deficits and partial improvement in motor deficits, suggesting that mHTT synthesized in the cortical neurons has a major role in the pathogenesis of behavioral deficits in BACHD mice. Finally, although we did not observe any significant improvement of the behavioral deficits and neuropathology in BR mice compared to BACHD mice ( Table 1) , these data should be interpreted with caution, as our power analyses ( Supplementary Table 1 ) suggest that a much larger sample size would be needed to conclusively show the absence of phenotypic improvement in BR mice.
To further explore the mechanisms underlying the differential rescue of disease phenotypes in our BACHD model series, we hypothesized that genetically reducing mHTT expression in cortical or striatal neurons may differentially affect corticostriatal synaptic communication, which is known to be altered in HD 24 . HD mouse models often recapitulate the loss of synaptic marker proteins, such as the presynaptic protein synaptophysin and the postsynaptic proteins actinin-2 (Actn2) and postsynaptic density-95 (PSD-95) (refs. [24] [25] [26] [27] [28] . Notably, both Actn2 and PSD-95 are expressed in the PSD of MSNs and functionally interact with NMDA receptors [29] [30] [31] . Reduction of PSD-95 expression has been implicated in NMDA receptor dysfunction in HD 24, 32 . By quantifying the immunofluorescence staining signals for these synaptic marker proteins in the dorsolateral striatal sections from 12-month-old mice, we found that BACHD mice express significantly lower amounts of all three synaptic marker proteins compared to WT mice ( Fig. 3a-d) . Notably, BR mice showed a significant increase in signals for both Actn2 and PSD-95 compared to BACHD mice, but their Actn2 levels were still lower than those in WT and BER mice (Fig. 3c) . Moreover, BR mice still exhibited significant loss of the presynaptic marker protein synaptophysin compared to WT mice (Fig. 3b) . This result suggests that reduction of PSD marker protein expression in MSNs is at least in part due to the cell-autonomous toxicities of mHTT within MSNs. In BE mice, we found a significant improvement of synaptophysin levels in the striatum (Fig. 3a,b) , as well as significant amelioration of both Actn2 and PSD-95 deficits compared to BACHD mice, but the level of Actn2 was still lower than in WT mice (Fig. 3a,c,d) . These results suggest that reduction of mHTT expression in CPNs can not only lead to cell-autonomous improvement of presynaptic marker protein levels in striatum (but originated from the CPNs), but also exert non-cell-autonomous benefits on the postsynaptic marker protein expression in the MSNs. Finally, BER mice showed amelioration of deficits in both presynaptic and postsynaptic marker proteins compared to BACHD mice, with their synaptic protein levels not differing from those in WT mice in our study. The Actn2 expression level in BER mice was significantly higher than that in BR mice (Fig. 3b-d) , which suggests that, at least for this PSD protein, the reduction of mHTT expression in both cortical and striatal neurons elicits further disease-amelioration benefit than reduction of mHTT expression in the striatal MSNs alone.
As reduction of mHTT expression in either the cortex or the striatum can increase the levels of postsynaptic proteins known to regulate NMDA receptor function [29] [30] [31] , we hypothesized that deficits in NMDA-mediated synaptic currents, if found in BACHD mice, would be ameliorated in BE or BR mice. To test this hypothesis, we examined striatal slices from BACHD, BE, BR and WT mice at a time at which disease was relatively advanced in the transgenic mice (13-15 months) for evoked synaptic NMDA currents. We found significantly impaired evoked synaptic NMDA currents in BACHD MSNs compared to those in WT MSNs (Fig. 3e,f) . Of note, similarly to their WT littermates, both BE and BR mice did not show deficits in evoked synaptic NMDA currents (Fig. 3e,f) . To further strengthen the observation that reduction of mHTT expression in the cortex can ameliorate striatal synaptic toxicities, we examined additional synaptic properties of MSNs in striatal slices from 12-month-old BE and BACHD mice. We found that BACHD MSNs exhibited a significant reduction of spontaneous excitatory postsynaptic currents (sEPSCs, frequencies at 5-15 pA) and an increase of spontaneous inhibitory postsynaptic currents (sIPSCs) compared to WT MSNs. These deficits were ameliorated in MSNs of BE mice (Supplementary Fig. 6 ). Taken together, these results indicate that mHTT in both striatal and cortical neurons contributes to the molecular and physiological deficits found in the synapses of striatal MSNs in BACHD mice. Moreover, we found that mHTT synthesized in cortical neurons elicits non-cell-autonomous toxicities that contribute to synaptic pathogenesis within striatal MSNs.
In summary, our study demonstrates a conceptually new conditional BAC transgenic approach to unveil the distinct but interacting roles of cortical and striatal mHTT in disease pathogenesis in a human genomic transgenic mouse model of HD.
We showed that highly selective reduction of mHTT expression in striatal MSNs contributed to the cell-autonomous amelioration of striatal postsynaptic deficits in BR mice. However, these mice still exhibited significant behavioral deficits and selective forebrain atrophy. Such findings should be interpreted with caution, as our power analyses showed that much larger numbers of mice are needed to fully exclude small phenotypic improvement between BR and BACHD mice ( Supplementary Table 1 ). Together, our results suggest that mHTT expression in striatal MSNs contributes to some aspects of striatal pathogenesis, but the pathogenesis of many behavioral and neurodegenerative phenotypes in BACHD is likely to require mHTT expression outside the striatal MSNs .
Our study is the first, to our knowledge, to evaluate the contribution of mHTT in cortical neurons in disease pathogenesis in a fl-mHTT transgenic mouse model of HD. A major finding in our study is that reduction of mHTT expression in the Emx1-Cre lineage, relatively restricted to the CPNs, leads to partial amelioration of motor deficits and improvement of psychiatric-like behavioral deficits. Our study also suggests that genetic reduction of mHTT expression in the cortex can elicit cell-autonomous improvement of presynaptic marker protein expression and non-cell-autonomous improvement of postsynaptic marker protein expression and synaptic neurotransmission within MSNs. This finding is consistent with our previous study demonstrating that pathological cell-cell interactions are necessary for disease pathogenesis in an mHTT fragment mouse model 15 . Our current study provides compelling evidence for non-cell-autonomous mHTT toxicities in striatal pathogenesis in a fl-mHTT mouse model and reveals that mHTT synthesized in the cortical neurons is a key source for such toxicities. Consistent with the emerging studies of other neurodegenerative disorders 8 , our results support the critical roles for non-cell-autonomous disease mechanisms in the pathogenesis and possibly therapy of HD.
The key finding in our current study, through the examination of BER mice, is that genetic reduction of mHTT expression in both cortical and striatal neurons results in the most robust amelioration of all disease-like phenotypes in BACHD mice. This result suggests an additive or synergistic role of cortical and striatal mHTT in HD pathogenesis. We favor the latter possibility because of the non-cell-autonomous roles for cortical mHTT in striatal synaptic pathogenesis. Future studies are needed to delineate the specific, and possibly distinct, molecular pathogenic mechanisms elicited by mHTT in the cortical and striatal neurons that are underpinning the corticostriatal pathological interactions in HD.
Finally, our study provides insights into where in the brain mHTT should be therapeutically targeted to ameliorate HD. To this end, we recognize some limitations of the study. BACHD mice, as well as other existing HD mouse models, only partially mimic the behavioral and neurodegenerative phenotypes of HD 33 . Moreover, the onset of Emx1-Cre and Rgs9-Cre activities is during embryonic and perinatal ages, respectively, and hence our study addresses reduction of regional mHTT synthesis in disease prevention rather than during therapeutic intervention after the disease onset. Therefore, our study cannot exclude the possibility of more therapeutic effects of reduction of striatal or cortical mHTT expression at ages when the disease phenotype has manifested 10, 11 . Notwithstanding such limitations, our study provides, to our knowledge, the first proof of concept on the benefit of targeting mHTT in the cortical neurons to partially ameliorate multiple behavioral deficits and to non-cell-autonomously improve striatal Supplementary Table 1 . (e) Evoked synaptic NMDA receptor-mediated currents in the MSNs of WT, BACHD, BE and BR mice. Representative traces (each trace is an average of 3 responses) of NMDA receptor-mediated currents in MSNs using patch-clamp recording in the presence of bicuculline and cyano-7-nitroquinoxaline-2,3-dione (n = 16 BACHD mice and n = 14 WT littermates; n = 11 BE mice and n = 10 WT littermates; n = 10 BR mice and n = 9 WT littermates). The ages of the mice were 13.3, 14.2 and 15.7 months of age for BACHD, BE and BR mice, respectively. V hold , holding potential. (f) Quantification of normalized amplitude of NMDA receptor-mediated currents in striatal MSNs from BACHD, BR and BE mice compared to those from WT mice. Two-way ANOVA followed by Bonferroni post hoc tests. Values represent means ± s.e.m., **P < 0.01. npg pathology in HD. It also suggests that the optimal therapeutic strategy may require the delivery of HTT-lowering therapies to both cortical and striatal neuronal targets in HD. Notably, strategies preferentially delivering such therapies to the cortex 12 or the striatum 10, 11 have been demonstrated in preclinical models. Future clinical trials will be needed to evaluate the distribution, efficacy and safety of these delivery strategies in patients with HD and to test whether the distinct but synergistic therapeutic benefits of lowering HTT in the cortex and striatum, as predicted by our study in an HD mouse model, can also be achieved in patients.
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ONLINE METHODS
Generation and breeding of conditional HD mice. BACHD mice were generated and maintained in the FVB/N background as described 3 . Emx1-Cre and Rgs9-Cre mice were backcrossed into the FVB/N background (>10 generations) and then bred to generate Emx1-Cre; Rgs9-Cre (ER) double-transgenic mice. BACHD and ER mice were bred to generate the cohort of mice with eight different genotypes: BACHD, BE, BR, BER, Emx1-Cre, Rgs9-Cre, Emx1-Cre; Rgs9-Cre and WT. All mice were maintained and bred under standard conditions consistent with NIH guidelines and approved by the Chancellor's Animal Research Committee at the University of California, Los Angeles. Genomic DNA was prepared from mouse tails, and BACHD and various Cre lines were genotyped using established PCR protocols 3, 15, 16 .
Cre reporter mouse assay. Emx1-Cre; Rgs9-Cre double-transgenic mice were mated with lacZ Cre reporter mice (Gt(ROSA)26Sor tm1Sor ) from the Jackson Laboratory (JAX003309). Brain sections from reporter mice crossed with Emx1-Cre, Rgs9-Cre or Emx1-Cre; Rgs9-Cre mice (postnatal day 90, one male and two female mice per genotype) were used to perform β-galactosidase histochemical assay using our established protocol 34 . Additionally, Emx1-Cre; Rgs9-Cre double-transgenic mice were mated with Ai3 (Gt(ROSA)26Sor tm3(CAG−EYFP)Hze ) Cre reporter mice from the Jackson Laboratory (JAX007903) 20 . One male and one female mice carrying cre and YFP transgenes were perfused with 4% paraformaldehyde in 0.1M PBS at postnatal day 90. Brains were postfixed overnight at 4 °C. Brain sections (20 µm in thickness) were prepared using a Leica 1800 Cryostat (Deerfield) and stained with anti-NeuN (1:1,000; mouse monoclonal antibody (mAb), Millipore MAB377) followed by Alexa Fluor 594-conjugated anti-mouse antibody (1:300; Life Technologies, A11005) based on our established protocols 15 .
Western blotting. Protein lysates and western blots were performed using our established protocols 3 . Immunoblots were probed with 1C2 (specific for expanded polyglutamine repeat; 1:3,000, Chemicon MAB1574) and antibody to α-tubulin (1:3,000; Sigma T9026) diluted in 5% blocking solution 3 . For quantification of western blots, two male and two female mice per genotype (3 months old) were used in the study.
In situ hybridization. The human mHTT fragment within the two loxP sites was cloned into pCR2.1-TOPO Vector using TOPO TA Cloning Kit (Life Technologies) and used as the cDNA template. RNA was labeled with 35 S-UTP using RNAMaxx High Yield Transcription Kit (Agilent) with T7 polymerase (Roche Applied Science). The radioactive in situ hybridization was performed using our established protocol 35 . One male and one female mouse per genotype (3 month old) were used in this study.
General experimental design. The sample sizes used for our experiments were predetermined based on the power analyses for longitudinal behavioral and neuropathological studies in BACHD mice 3, 14 . For our study, randomization and allocation of a given genotype is not necessary and hence was not performed. No individual data points were excluded from the statistical analyses. Sex-matched mice of appropriate genotypes were used for behavioral and neuropathological studies by investigators who were blinded to the genotypes.
Behavioral studies.
Rotarod and open-field exploration tests were performed for BACHD, WT, BE, BR and BER mice generated from BACHD × Emx1-Cre; Rgs9-Cre double-transgenic Cre mice at 2, 6 and 12 months of age (n = 12-15 per genotype, with almost equal number from each gender) using our established protocols 3 . The psychiatric-like behavioral tests were performed on the above mice at 12 months of age. The light-dark exploration tests were performed as described before 36 . The forced swimming tests were performed using a standard protocol. Briefly, mice were allowed to acclimate to the experimental room at least 1 hour before testing. One mouse was put into a Plexiglas tank or a transparent plastic cylinder (15-cm diameter) filled with water (25 °C) to a height of 25 cm and videotaped for 6 min. The last 4 min of video was used to score for immobility, which was defined as absence of all movement except motions required for keeping the head above the water. Time spent immobile was recorded and analyzed. Open-field testing was performed during the dark phase of the light-dark cycle, whereas other behavioral tests were performed during the light phase.
Neurodegenerative pathology. The analyses of forebrain weight, cerebellar weight and unbiased stereological measurements of cortical and striatal volumes in BACHD, BE, BR, BER and WT mice (n = 8 per genotype, four male and four female) at 12 months of age were performed using our established protocols 3, 36 .
Detection of presynaptic and postsynaptic marker proteins by immunofluorescence and quantification of the indirect fluorescent signal intensities.
Twelve-month-old BACHD, BE, BR, BER and WT mice (n = 7-10 per genotype, with almost equal number from each gender) were used for indirect immunofluorescent staining for synaptophysin, Actn2 and PSD-95 in the striatum. Antibodies against synaptophysin (mouse Alexa Fluor 488-conjugated mAb, MAB5258A4, Millipore), Actn2 (rabbit mAb, EP2529Y, Epitomics) and PSD-95 (mouse mAb, 75-028, UC Davis/NIH NeuroMab Facility) were used following manufacturer instructions with modification. Thin coronal brain sections (5 µm) containing dorsal striatum (near bregma +1.2 mm) were prepared and immunostained with antibodies against synaptophysin (1:200), Actn2 (1:500) or PSD-95 (1:500). The latter two were followed by goat anti-rabbit or goat anti-mouse secondary antibody conjugated to Alexa Fluor 594 (1:300, A11037 and A11005, Life Technologies). For each mouse, two randomly selected dorsal striatal regions (near bregma +1.2 mm) were imaged at high magnification (63×) using a Zeiss LSM510 confocal laser-scanning microscope. The indirect immunofluorescence intensities of the images were measured using ImageJ software (NIH). All images for different genotypes were obtained and processed under identical conditions. Slice electrophysiological recordings. Whole-cell patch clamp recordings from MSNs were obtained using standard methods 26 . Cells were identified by soma size and basic membrane properties (input resistance, capacitance and time constant). The patch pipette (3-5 MΩ) contained the following solution (in mM): cesium methanesulfonate (130), CsCl (10), NaCl (4), MgCl 2 (1), Mg-ATP (5), EGTA (5), HEPES (10), GTP (0.5), phosphocreatine (10) and leupeptin (0.1) (pH 7.25-7.3, osmolality, 280-290 mOsm). Spontaneous postsynaptic currents were recorded in standard artificial cerebrospinal fluid (ACSF) composed of the following: NaCl130 mM, NaHCO 3 26 mM, KCl 3 mM, MgCl 2 2 mM, NaHPO 4 1.25 mM, CaCl 2 2 mM and glucose 10 mM (pH 7.4, osmolality, 300 mOsm). After characterizing the basic membrane properties of the neuron, NMDA receptor-mediated synaptic currents were evoked by electrical stimulation of afferent cortical fibers using a metal bipolar stimulating electrode. The stimulating electrode was placed on the dorsolateral corpus callosum 150-250 µm from the recording electrode. Stimuli (0.5-ms pulse duration, 0.1-to 1.0-mA intensity) were delivered at intervals of approximately 30 s. Evoked NMDA receptor-mediated EPSCs were recorded at a holding potential of +40 mV ACSF containing 10 µM BIC, a GABA A receptor antagonist, and 10 µM 6-cyano-7-nitroquinoxaline-2,3-dione. Recording electrodes also contained QX-314 to block Na + channel-mediated currents. Evoked NMDA currents were recorded on MSNs from 13-to 15-month old mice (n = 5 for BACHD and 5 WT littermates, 3 males and 2 females per genotype; n = 4 BE and 4 WT littermates, 2 males and 2 females per genotype; n = 3 BR and 3 WT littermates, 2 males and one female per genotype). Spontaneous EPSCs were recorded on MSNs from 10-to 11-month-old BACHD, BE and WT littermate mice (n = 4 per genotype, two males and two females). Spontaneous EPSCs were recorded on MSNs from 12-to 13-month-old BACHD, BE and WT littermate mice (n = 4 per genotype, two males and two females).
Statistical analyses.
All data are shown as the mean ± s.e.m. SPSS 17.0 statistics software was used to perform all of the statistical analyses. Oneway ANOVA followed by LSD post hoc analysis was used. The minimum significance level was set at P < 0.05. 
